Tags

Type your tag names separated by a space and hit enter

Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
Lancet. 1984 Oct 06; 2(8406):782-4.Lct

Abstract

In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 injection, was not statistically significant. No side-effects and no rebound phenomenon were observed. These results suggest that SMS 201-995 may be the first somatostatin analogue suitable for the clinical management of acromegaly.

Links

Publisher Full Text

Authors

Plewe G
No affiliation info available
Beyer J
No affiliation info available
Krause U
No affiliation info available
Neufeld M
No affiliation info available
del Pozo E
No affiliation info available

MeSH

AcromegalyAdultAgedEatingGlucagonGlucose Tolerance TestGrowth HormoneHumansInsulinMiddle AgedOctreotideSomatostatinTime Factors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6148524

Citation

Plewe, G, et al. "Long-acting and Selective Suppression of Growth Hormone Secretion By Somatostatin Analogue SMS 201-995 in Acromegaly." Lancet (London, England), vol. 2, no. 8406, 1984, pp. 782-4.
Plewe G, Beyer J, Krause U, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. 1984;2(8406):782-4.
Plewe, G., Beyer, J., Krause, U., Neufeld, M., & del Pozo, E. (1984). Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet (London, England), 2(8406), 782-4.
Plewe G, et al. Long-acting and Selective Suppression of Growth Hormone Secretion By Somatostatin Analogue SMS 201-995 in Acromegaly. Lancet. 1984 Oct 6;2(8406):782-4. PubMed PMID: 6148524.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. AU - Plewe,G, AU - Beyer,J, AU - Krause,U, AU - Neufeld,M, AU - del Pozo,E, PY - 1984/10/6/pubmed PY - 1984/10/6/medline PY - 1984/10/6/entrez SP - 782 EP - 4 JF - Lancet (London, England) JO - Lancet VL - 2 IS - 8406 N2 - In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 injection, was not statistically significant. No side-effects and no rebound phenomenon were observed. These results suggest that SMS 201-995 may be the first somatostatin analogue suitable for the clinical management of acromegaly. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/6148524/Long_acting_and_selective_suppression_of_growth_hormone_secretion_by_somatostatin_analogue_SMS_201_995_in_acromegaly_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(84)90706-2 DB - PRIME DP - Unbound Medicine ER -